My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes - Episode 3
Navigating Continuous BTKi Therapy for CLL in the 1L Setting
John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.
Video content above is prompted by the following questions:
- How do you select patients for first-line treatment with continuous BTKi therapy? How do available long-term data influence your decision?